
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/base_style-CPPDhfna.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-BepKMsUl.js"></script>

  <link rel="stylesheet" href="/static/assets/article_style-DUfI1jZp.css" />
<link rel="stylesheet" href="/static/assets/style-BOrsu84o.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-D3wJHomh.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="E0CA25D3930B24530025D3001A9EAE07.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="ijms">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11899880/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="International Journal of Molecular Sciences">
<meta name="citation_title" content="Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review">
<meta name="citation_author" content="Ignacio Ventura">
<meta name="citation_author_institution" content="Molecular and Mitochondrial Medicine Research Group, School of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; ignacio.ventura@ucv.es">
<meta name="citation_author_institution" content="Translational Research Center San Alberto Magno CITSAM, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain">
<meta name="citation_author" content="Nerea Pinilla Salcedo">
<meta name="citation_author_institution" content="School of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; nepisal@mail.ucv.es">
<meta name="citation_author" content="Marcelino Pérez-Bermejo">
<meta name="citation_author_institution" content="SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; javier.perezmu@ucv.es (J.P.-M.); manuel.tejeda@ucv.es (M.T.-A.); paco.tomas@ucv.es (F.T.-A.); ester.legidos@ucv.es (M.E.L.-G.); mt.murillo@ucv.es (M.T.M.-L.)">
<meta name="citation_author" content="Javier Pérez-Murillo">
<meta name="citation_author_institution" content="SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; javier.perezmu@ucv.es (J.P.-M.); manuel.tejeda@ucv.es (M.T.-A.); paco.tomas@ucv.es (F.T.-A.); ester.legidos@ucv.es (M.E.L.-G.); mt.murillo@ucv.es (M.T.M.-L.)">
<meta name="citation_author" content="Manuel Tejeda-Adell">
<meta name="citation_author_institution" content="SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; javier.perezmu@ucv.es (J.P.-M.); manuel.tejeda@ucv.es (M.T.-A.); paco.tomas@ucv.es (F.T.-A.); ester.legidos@ucv.es (M.E.L.-G.); mt.murillo@ucv.es (M.T.M.-L.)">
<meta name="citation_author" content="Francisco Tomás-Aguirre">
<meta name="citation_author_institution" content="SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; javier.perezmu@ucv.es (J.P.-M.); manuel.tejeda@ucv.es (M.T.-A.); paco.tomas@ucv.es (F.T.-A.); ester.legidos@ucv.es (M.E.L.-G.); mt.murillo@ucv.es (M.T.M.-L.)">
<meta name="citation_author" content="María Ester Legidos-García">
<meta name="citation_author_institution" content="SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; javier.perezmu@ucv.es (J.P.-M.); manuel.tejeda@ucv.es (M.T.-A.); paco.tomas@ucv.es (F.T.-A.); ester.legidos@ucv.es (M.E.L.-G.); mt.murillo@ucv.es (M.T.M.-L.)">
<meta name="citation_author" content="María Teresa Murillo-Llorente">
<meta name="citation_author_institution" content="SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; javier.perezmu@ucv.es (J.P.-M.); manuel.tejeda@ucv.es (M.T.-A.); paco.tomas@ucv.es (F.T.-A.); ester.legidos@ucv.es (M.E.L.-G.); mt.murillo@ucv.es (M.T.M.-L.)">
<meta name="citation_publication_date" content="2025 Feb 23">
<meta name="citation_volume" content="26">
<meta name="citation_issue" content="5">
<meta name="citation_firstpage" content="1908">
<meta name="citation_doi" content="10.3390/ijms26051908">
<meta name="citation_pmid" content="40076535">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11899880/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11899880/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11899880/pdf/ijms-26-01908.pdf">
<meta name="description" content="Breast cancer is the most clinically relevant pathology of the mammary gland and is currently the most diagnosed malignant disease among women worldwide. In breast cancer prevention, it is important to consider that the risk of developing the ...">
<meta name="og:title" content="Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Breast cancer is the most clinically relevant pathology of the mammary gland and is currently the most diagnosed malignant disease among women worldwide. In breast cancer prevention, it is important to consider that the risk of developing the ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC11899880/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="11899880">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.3390/ijms26051908"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/ijms-26-01908.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11899880%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/11899880/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/11899880/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11899880/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-ijms.png" alt="International Journal of Molecular Sciences logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to International Journal of Molecular Sciences" title="Link to International Journal of Molecular Sciences" shape="default" href="http://www.mdpi.com/journal/ijms/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Int J Mol Sci</button></div>. 2025 Feb 23;26(5):1908. doi: <a href="https://doi.org/10.3390/ijms26051908" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.3390/ijms26051908</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Int%20J%20Mol%20Sci%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Int%20J%20Mol%20Sci%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Int%20J%20Mol%20Sci%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Int%20J%20Mol%20Sci%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ventura%20I%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Ignacio Ventura</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Ignacio Ventura</span></h3>
<div class="p">
<sup>1</sup>Molecular and Mitochondrial Medicine Research Group, School of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; ignacio.ventura@ucv.es</div>
<div class="p">
<sup>2</sup>Translational Research Center San Alberto Magno CITSAM, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ventura%20I%22%5BAuthor%5D" class="usa-link"><span class="name western">Ignacio Ventura</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Salcedo%20NP%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Nerea Pinilla Salcedo</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Nerea Pinilla Salcedo</span></h3>
<div class="p">
<sup>3</sup>School of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; nepisal@mail.ucv.es</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Salcedo%20NP%22%5BAuthor%5D" class="usa-link"><span class="name western">Nerea Pinilla Salcedo</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22P%C3%A9rez-Bermejo%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Marcelino Pérez-Bermejo</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Marcelino Pérez-Bermejo</span></h3>
<div class="p">
<sup>4</sup>SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; javier.perezmu@ucv.es (J.P.-M.); manuel.tejeda@ucv.es (M.T.-A.); paco.tomas@ucv.es (F.T.-A.); ester.legidos@ucv.es (M.E.L.-G.); mt.murillo@ucv.es (M.T.M.-L.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22P%C3%A9rez-Bermejo%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Marcelino Pérez-Bermejo</span></a>
</div>
</div>
<sup>4,</sup><sup>*</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22P%C3%A9rez-Murillo%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Javier Pérez-Murillo</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Javier Pérez-Murillo</span></h3>
<div class="p">
<sup>4</sup>SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; javier.perezmu@ucv.es (J.P.-M.); manuel.tejeda@ucv.es (M.T.-A.); paco.tomas@ucv.es (F.T.-A.); ester.legidos@ucv.es (M.E.L.-G.); mt.murillo@ucv.es (M.T.M.-L.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22P%C3%A9rez-Murillo%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Javier Pérez-Murillo</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tejeda-Adell%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Manuel Tejeda-Adell</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Manuel Tejeda-Adell</span></h3>
<div class="p">
<sup>4</sup>SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; javier.perezmu@ucv.es (J.P.-M.); manuel.tejeda@ucv.es (M.T.-A.); paco.tomas@ucv.es (F.T.-A.); ester.legidos@ucv.es (M.E.L.-G.); mt.murillo@ucv.es (M.T.M.-L.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tejeda-Adell%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Manuel Tejeda-Adell</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tom%C3%A1s-Aguirre%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Francisco Tomás-Aguirre</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Francisco Tomás-Aguirre</span></h3>
<div class="p">
<sup>4</sup>SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; javier.perezmu@ucv.es (J.P.-M.); manuel.tejeda@ucv.es (M.T.-A.); paco.tomas@ucv.es (F.T.-A.); ester.legidos@ucv.es (M.E.L.-G.); mt.murillo@ucv.es (M.T.M.-L.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tom%C3%A1s-Aguirre%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Francisco Tomás-Aguirre</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Legidos-Garc%C3%ADa%20ME%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">María Ester Legidos-García</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">María Ester Legidos-García</span></h3>
<div class="p">
<sup>4</sup>SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; javier.perezmu@ucv.es (J.P.-M.); manuel.tejeda@ucv.es (M.T.-A.); paco.tomas@ucv.es (F.T.-A.); ester.legidos@ucv.es (M.E.L.-G.); mt.murillo@ucv.es (M.T.M.-L.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Legidos-Garc%C3%ADa%20ME%22%5BAuthor%5D" class="usa-link"><span class="name western">María Ester Legidos-García</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Murillo-Llorente%20MT%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">María Teresa Murillo-Llorente</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">María Teresa Murillo-Llorente</span></h3>
<div class="p">
<sup>4</sup>SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; javier.perezmu@ucv.es (J.P.-M.); manuel.tejeda@ucv.es (M.T.-A.); paco.tomas@ucv.es (F.T.-A.); ester.legidos@ucv.es (M.E.L.-G.); mt.murillo@ucv.es (M.T.M.-L.)</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Murillo-Llorente%20MT%22%5BAuthor%5D" class="usa-link"><span class="name western">María Teresa Murillo-Llorente</span></a>
</div>
</div>
<sup>4</sup>
</div>
<div class="cg p">Editors: <span class="name western">Stergios Boussios</span>, <span class="name western">Matin Sheriff</span>, <span class="name western">Saak Victor Ovsepian</span>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="af1-ijms-26-01908">
<sup>1</sup>Molecular and Mitochondrial Medicine Research Group, School of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; ignacio.ventura@ucv.es</div>
<div id="af2-ijms-26-01908">
<sup>2</sup>Translational Research Center San Alberto Magno CITSAM, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain</div>
<div id="af3-ijms-26-01908">
<sup>3</sup>School of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; nepisal@mail.ucv.es</div>
<div id="af4-ijms-26-01908">
<sup>4</sup>SONEV Research Group, Faculty of Medicine and Health Sciences, Catholic University of Valencia San Vicente Mártir, C/Quevedo nº 2, 46001 Valencia, Spain; javier.perezmu@ucv.es (J.P.-M.); manuel.tejeda@ucv.es (M.T.-A.); paco.tomas@ucv.es (F.T.-A.); ester.legidos@ucv.es (M.E.L.-G.); mt.murillo@ucv.es (M.T.M.-L.)</div>
<div class="author-notes p"><div class="fn" id="c1-ijms-26-01908">
<sup>*</sup><p class="display-inline">Correspondence: <span>marcelino.perez@ucv.es</span>; Tel.: +34-620984639</p>
</div></div>
<h4 class="font-secondary">Roles</h4>
<div class="p">
<strong class="contrib"><span class="name western">Stergios Boussios</span></strong>: <span class="role">Academic Editor</span>
</div>
<div>
<strong class="contrib"><span class="name western">Matin Sheriff</span></strong>: <span class="role">Academic Editor</span>
</div>
<div>
<strong class="contrib"><span class="name western">Saak Victor Ovsepian</span></strong>: <span class="role">Academic Editor</span>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Feb 5; Revised 2025 Feb 19; Accepted 2025 Feb 21; Collection date 2025 Mar.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 by the authors.</div>
<p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by/4.0/</a>).</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC11899880  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40076535/" class="usa-link">40076535</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Breast cancer is the most clinically relevant pathology of the mammary gland and is currently the most diagnosed malignant disease among women worldwide. In breast cancer prevention, it is important to consider that the risk of developing the disease is not the same for the entire population. This pathology presents heterogeneous clinical manifestations and the most common classification is related to the following hormonal receptors: estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and triple-negative (TNBC). Currently, a new class of therapy is being used for cancer treatment: anti-body-drug conjugates. A bibliographic search was performed by establishing keywords and then combining them using Boolean operators OR and AND. Thus, the search equation was formulated according to the PICO search question to be used in the PubMed database. Results: Fifteen studies that met the established inclusion criteria were analyzed, and their methodological quality was assessed using the Joanna Briggs Institute approach, demonstrating high reliability in the results obtained, the analyzed studies focus on the combination of adjuvant Pertuzumab + Trastuzumab with chemotherapy for the treatment of HER2-positive breast cancer. Scientific evidence suggests that the combination of pertuzumab and trastuzumab not only improves the survival of patients with HER2-positive breast cancer but also provides a safe and flexible treatment option.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> breast cancer, human epidermal growth factor receptor 2 (HER2), trastuzumab, pertuzumab</p></section></section><section id="sec1-ijms-26-01908"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Breast cancer (BC) is the most clinically relevant pathology of the mammary gland. It has become the most commonly diagnosed malignancy in women worldwide and is the leading cause of cancer death in women aged 20–59 years according to the latest GLOBOCAN data. However, it is rare in men, accounting for 1% of cancer diagnoses. BC (Breast Cancer) is a disease with heterogeneous clinical manifestations and is classified into numerous subtypes that have evolved over the years [<a href="#B1-ijms-26-01908" class="usa-link" aria-describedby="B1-ijms-26-01908">1</a>,<a href="#B2-ijms-26-01908" class="usa-link" aria-describedby="B2-ijms-26-01908">2</a>]. The most common and widely accepted classification is based on an immunohistochemical perspective related to the following hormone receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor (HER2). It is also considered an important marker in the presence and recurrence of tumors and triple-negative (TNBC) [<a href="#B3-ijms-26-01908" class="usa-link" aria-describedby="B3-ijms-26-01908">3</a>]. The following subtypes of breast cancer are identified: Luminal A, Luminal B, HER2 positive, and triple negative.</p>
<p>Breast cancer staging is used to classify patients into risk categories that determine prognosis and treatment recommendations. It is based on physical examination and imaging studies, as well as pathological examination of the primary tumor and lymph nodes. The most commonly used TNM staging system is that of the American Joint Committee on Cancer, which divides patients into four groups according to the size of the primary tumor (T), regional lymph node status (N), and the presence of distant metastases (M) [<a href="#B4-ijms-26-01908" class="usa-link" aria-describedby="B4-ijms-26-01908">4</a>]. Stage 0 includes non-invasive BC and ductal carcinoma in situ. Stages I, IIa, and IIb represent early invasive BC. Stages IIIa, IIIb, and IIIc include locally advanced BC, while stage IV includes all metastatic BC. Stage II breast cancer is divided into stages IIa and IIb based on the size of the tumor and the involvement of lymph nodes. Stage IIa refers to tumors that are either smaller than 2 cm but have spread to 1–3 axillary lymph nodes or are 2–5 cm in size without lymph node involvement. In contrast, stage IIb describes tumors that are 2–5 cm in size with 1–3 lymph nodes affected or larger than 5 cm without nodal involvement. Stage III breast cancer, categorized into IIIa, IIIb, and IIIc, reflects more advanced disease. Stage IIIa involves extensive lymph node involvement (4–9 axillary nodes or internal mammary nodes) regardless of tumor size, while stage IIIb includes tumors of any size that have invaded the chest wall or skin. Stage IIIc is defined by the involvement of 10 or more axillary lymph nodes, infraclavicular or supraclavicular nodes, or both, regardless of tumor size or invasion of nearby structures [<a href="#B4-ijms-26-01908" class="usa-link" aria-describedby="B4-ijms-26-01908">4</a>,<a href="#B5-ijms-26-01908" class="usa-link" aria-describedby="B5-ijms-26-01908">5</a>].</p>
<p>Breast cancer has become the most commonly diagnosed cancer worldwide, surpassing lung and prostate cancers. Developed countries have the highest incidence of breast cancer, although this may be due to better detection of this pathology. The mortality rate varies widely among regions, being higher in low socioeconomic areas due to fewer resources to detect the disease and difficulty in accessing adequate treatment [<a href="#B6-ijms-26-01908" class="usa-link" aria-describedby="B6-ijms-26-01908">6</a>].</p>
<p>In women’s health screening, it is important to identify risk factors associated with a higher incidence of breast cancer. There are non-modifiable risk factors and modifiable risk factors. Non-modifiable risk factors are age, gender, histologic risk factors, genetic risk factors and family history, exogenous hormones, and reproductive risk factors. The modifiable risk factors are physical activity and diet, obesity, alcohol consumption, and smoking [<a href="#B4-ijms-26-01908" class="usa-link" aria-describedby="B4-ijms-26-01908">4</a>,<a href="#B7-ijms-26-01908" class="usa-link" aria-describedby="B7-ijms-26-01908">7</a>,<a href="#B8-ijms-26-01908" class="usa-link" aria-describedby="B8-ijms-26-01908">8</a>].</p>
<p>Treatments for BC have been extensively developed over the past few decades, and thanks to improved therapeutic approaches, most patients with early-stage breast cancer are curable. Although survival has improved for patients with advanced BC, it is still incurable. A new class of targeted cancer therapy is currently being used: antibody–drug conjugates (ADCs), which consist of a monoclonal antibody conjugated to a cytotoxic agent via a chemical linker. This unique structure develops specific cytotoxicity against tumor cells [<a href="#B2-ijms-26-01908" class="usa-link" aria-describedby="B2-ijms-26-01908">2</a>].</p>
<p>The standard first-line treatment for HER2-positive breast cancer has historically been trastuzumab in combination with chemotherapy. However, recent research suggests that the combination of pertuzumab and trastuzumab in the adjuvant setting may offer significant benefits in terms of survival and response to treatment. This study is justified by the need to determine the feasibility and efficacy of combination therapy with pertuzumab and trastuzmab in critically ill patients.</p>
<p>It is critical to evaluate the advisability and safety of this therapeutic combination in the ICU setting, where patients may have increased frailty and associated complications. In addition, it is important to analyze the potential side effects and their management in the ICU setting to ensure that the implementation of this combination therapy does not compromise patient stability. Improving disease-free survival with combination therapy in HER2+ breast cancer: This illustrative schematic shows the difference between a breast cancer cell in the healthy state and one in the diseased (HER2+) state. In the healthy state, HER2 receptors on the cell surface send signals that regulate cell growth and division. In the diseased state, an excess of HER2 receptors sends more signals than normal, leading to uncontrolled cell growth. Combination therapy with trastuzumab, docetaxel, and pertuzumab targets these HER2 receptors and improves disease-free survival in patients with HER2+ breast cancer. Trastuzumab and pertuzumab are monoclonal antibodies that target the HER2 receptor at different sites. Trastuzumab blocks cell proliferation by inhibiting receptor dimerization, while pertuzumab prevents growth signaling by binding to a different HER2 epitope. Docetaxel is an antimitotic agent that inhibits microtubule depolymerization by specifically binding to tubulin subunits, thereby stabilizing microtubule assembly and disrupting cell division (<a href="#ijms-26-01908-f001" class="usa-link">Figure 1</a>). Given the diverse clinical scenarios in HER2-positive breast cancer, including neoadjuvant, adjuvant, and metastatic settings, this review aims to systematically evaluate the efficacy and safety of combining pertuzumab, trastuzumab, and docetaxel. To address the heterogeneity of patient populations and study designs, we categorized the evidence based on treatment intent, end points, and toxicity profiles. This approach seeks to provide a comprehensive yet structured analysis, facilitating the translation of findings into clinical practice.</p>
<figure class="fig xbox font-sm" id="ijms-26-01908-f001"><h3 class="obj_head">Figure 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11899880_ijms-26-01908-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb2d/11899880/0dd3cf1a932a/ijms-26-01908-g001.jpg" loading="lazy" height="484" width="795" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/ijms-26-01908-f001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Improved disease-free survival with combination therapy in HER2+ breast cancer: This illustrative schematic shows the difference between a healthy and a diseased (HER2+) breast cancer cell. In the healthy state, HER2 receptors on the cell surface send signals that regulate cell growth and division. In the diseased state, an excess of HER2 receptors sends more signals than normal, leading to uncontrolled cell growth. Combination therapy with trastuzumab, docetaxel, and pertuzumab targets these HER2 receptors and improves disease-free survival in patients with HER2+ breast cancer. Trastuzumab and pertuzumab are monoclonal antibodies that target the HER2 receptor at different sites. Trastuzumab blocks cell proliferation by inhibiting receptor dimerization, while pertuzumab prevents growth signals by binding to a different HER2 epitope. Docetaxel prevents the polymerization of microtubules necessary for tumor cell mitosis, thereby interrupting cell division and promoting cell death.</p></figcaption></figure></section><section id="sec2-ijms-26-01908"><h2 class="pmc_sec_title">2. Methods</h2>
<p>This work is a systematic review conducted in accordance with the criteria set out in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) [<a href="#B9-ijms-26-01908" class="usa-link" aria-describedby="B9-ijms-26-01908">9</a>] guidelines which was registered in the records of the Open Science Framework (<a href="https://osf.io/gsyme" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://osf.io/gsyme</a>; accessed 23 December 2024). The PRISMA 2020 checklist (<a href="#app1-ijms-26-01908" class="usa-link">Supplementary Data S1</a>) was also applied. The main idea is to know the use of the biopharmaceutical trastuzumab in combination with pertuzumab in the treatment of breast cancer, as well as its adverse effects. The search was conducted in the Cochrane and PubMed databases to ensure a broad and rigorous coverage of the available scientific literature. The equation was formed by combining the previously established descriptors using the Boolean operators “AND” and “OR” and is as follows ((HUMAN EPIDERMAL GROWTH FACTOR) OR (HER2)) AND (BREAST CANCER OR BREAST CARCINOMA OR BREAST NEOPLASIA) AND PERTUZUMAB AND TRASTUZUMAB AND CHEMOTHERAPY.</p>
<p>To conduct this literature search, it is necessary to formulate the research question following the steps of the PICO format (<a href="#ijms-26-01908-t001" class="usa-link">Table 1</a>). The question is as follows: “In patients with HER2-positive breast cancer, is the combined treatment of pertuzumab and trastuzumab more effective than trastuzumab and conventional chemotherapy in improving progression-free survival and pathologic complete response in controlled clinical trials?</p>
<section class="tw xbox font-sm" id="ijms-26-01908-t001"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>PICOS research question.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr>
<td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Patient (P)</td>
<td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">HER2-positive breast cancer patients.</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Intervention (I)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Comparison of the binding of two drugs to HER2+ breast cancer progression.</td>
</tr>
<tr>
<td align="center" valign="middle" rowspan="1" colspan="1">Comparison (C)</td>
<td align="center" valign="middle" rowspan="1" colspan="1">Pertuzumab combined with trastuzumab versus trastuzumab with conventional chemotherapy.</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Outcome (O)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Efficacy of combination therapy and improvement in progression-free survival and pathologic complete response rate.</td>
</tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/ijms-26-01908-t001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><section id="sec2dot1-ijms-26-01908"><h3 class="pmc_sec_title">2.1. Inclusion and Exclusion Criteria</h3>
<section id="sec2dot1dot1-ijms-26-01908"><h4 class="pmc_sec_title">2.1.1. Inclusion Criteria</h4>
<ul class="list" style="list-style-type:none">
<li>
<span class="label">-</span><p class="display-inline">Published studies with full text: only studies that are available in their entirety will be considered to ensure a comprehensive and accurate analysis.</p>
</li>
<li>
<span class="label">-</span><p class="display-inline">Human studies: the search will focus exclusively on studies with human patients to ensure the clinical relevance of the results.</p>
</li>
<li>
<span class="label">-</span><p class="display-inline">Published within the last 10 years: to ensure that the data are current and reflect the most recent advances in the treatment of HER2-positive breast cancer.</p>
</li>
<li>
<span class="label">-</span><p class="display-inline">Published in English: English language studies will be selected to ensure accessibility and consistency in the literature review.</p>
</li>
</ul></section><section id="sec2dot1dot2-ijms-26-01908"><h4 class="pmc_sec_title">2.1.2. Exclusion Criteria </h4>
<ul class="list" style="list-style-type:none">
<li>
<span class="label">-</span><p class="display-inline">Animal studies: studies using animal models will be excluded as the results may not be directly applicable to humans.</p>
</li>
<li>
<span class="label">-</span><p class="display-inline">Studies without scientific evidence: studies that do not present data based on sound scientific evidence or that do not meet adequate methodological standards will be discarded.</p>
</li>
</ul>
<p>The initial search yielded a total of 1236 articles. The flowchart in <a href="#ijms-26-01908-f002" class="usa-link">Figure 2</a> describes the screening and selection process. </p>
<figure class="fig xbox font-sm" id="ijms-26-01908-f002"><h5 class="obj_head">Figure 2.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=11899880_ijms-26-01908-g002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb2d/11899880/a1d258c48f5f/ijms-26-01908-g002.jpg" loading="lazy" height="737" width="785" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/ijms-26-01908-f002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>PRISMA flowchart of the study selection process.</p></figcaption></figure></section></section></section><section id="sec3-ijms-26-01908"><h2 class="pmc_sec_title">3. Results and Discussion</h2>
<p>After a first reading of the title and results, the selection was reduced to 1173 articles, of which 40 were excluded after a complete reading of each and after verifying that they were not the objective of this work. Applying the inclusion and exclusion criteria, 126 articles were selected, and after the number of records excluded due to incompatibility with the purpose of the study, 15 articles were included. These studies were graded according to the corresponding checklist of the Joanna Briggs Institute (JBI) [<a href="#B10-ijms-26-01908" class="usa-link" aria-describedby="B10-ijms-26-01908">10</a>] and all of them were scored as 100%. <a href="#ijms-26-01908-t002" class="usa-link">Table 2</a> shows the main characteristics of each study.</p>
<section class="tw xbox font-sm" id="ijms-26-01908-t002"><h3 class="obj_head">Table 2.</h3>
<div class="caption p"><p>The main characteristics of each study were analyzed.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">n</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Objective</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Intervention</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Outcomes</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Most Common AE</th>
</tr></thead>
<tbody>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B11-ijms-26-01908" class="usa-link" aria-describedby="B11-ijms-26-01908">11</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">808</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compare the efficacy and safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab + <br>Trastuzumab + <br>Docetaxel vs. <br>Placebo + Trastuzumab + Docetaxel</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved median overall survival (57.1 months vs. 40.8 months)</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc">
<li><p>Neutropenia </p></li>
<li><p>Congestive heart failure</p></li>
</ul>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B12-ijms-26-01908" class="usa-link" aria-describedby="B12-ijms-26-01908">12</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">266</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluate treatment patterns and outcomes in real-world settings</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trastuzumab + Pertuzumab + Taxane</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median progression-free survival: 16.9 months</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc">
<li><p>Fatigue </p></li>
<li><p>Diarrhea </p></li>
<li><p>Nausea </p></li>
<li><p>Peripheral neuropathy</p></li>
</ul>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B13-ijms-26-01908" class="usa-link" aria-describedby="B13-ijms-26-01908">13</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2836</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Assess the benefits of dual HER2 therapy over single HER2 therapy</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dual HER2 therapy vs. Single HER2 therapy</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased complete pathologic response</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc"><li><p>Varied across studies</p></li></ul>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B14-ijms-26-01908" class="usa-link" aria-describedby="B14-ijms-26-01908">14</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">444</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compare neoadjuvant regimens for HER2+ BC</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trastuzumab emtansine + Pertuzumab vs. Docetaxel + Carboplatin + Trastuzumab + Pertuzumab</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Higher complete pathologic response with chemotherapy combination</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc">
<li><p>Neutropenia </p></li>
<li><p>Diarrhea</p></li>
</ul>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B15-ijms-26-01908" class="usa-link" aria-describedby="B15-ijms-26-01908">15</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">258</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluate the impact of adding Pertuzumab to Trastuzumab + Aromatase Inhibitor</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab + Trastuzumab + Aromatase Inhibitor vs. Trastuzumab alone</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median progression-free survival: 18.89 vs. 15.80 months</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc">
<li><p>Diarrhea </p></li>
<li><p>Alopecia </p></li>
<li><p>Nausea</p></li>
</ul>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B16-ijms-26-01908" class="usa-link" aria-describedby="B16-ijms-26-01908">16</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">524</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compare Trastuzumab deruxtecan vs. Trastuzumab emtasine</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trastuzumab deruxtecan vs. Trastuzumab emtasine</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PFS: 29.1 months vs. 7.2 months</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc">
<li><p>Pneumonitis, </p></li>
<li><p>Pneumonia</p></li>
</ul>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B17-ijms-26-01908" class="usa-link" aria-describedby="B17-ijms-26-01908">17</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2023</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">243</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluate Pertuzumab in combination therapy</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab + Trastuzumab + Docetaxel vs. Placebo</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median PFS: 16.5 vs. 12.5 months</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc">
<li><p>Leukopenia </p></li>
<li><p>Anemia </p></li>
<li><p>Diarrhea</p></li>
</ul>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B18-ijms-26-01908" class="usa-link" aria-describedby="B18-ijms-26-01908">18</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1095</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compare Trastuzumab emtansine ± Pertuzumab vs. Trastuzumab + Taxane</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trastuzumab emtansine ± Pertuzumab vs. Trastuzumab + Taxane</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No superiority in PFS</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc"><li><p>Lower alopecia and diarrhea in the emtansine arm</p></li></ul>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B19-ijms-26-01908" class="usa-link" aria-describedby="B19-ijms-26-01908">19</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">558</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluate adjuvant therapy with Pertuzumab + Trastuzumab</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab + Trastuzumab + Chemotherapy</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved adjuvant treatment outcomes</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc">
<li><p>Diarrhea </p></li>
<li><p>Febrile neutropenia</p></li>
</ul>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B20-ijms-26-01908" class="usa-link" aria-describedby="B20-ijms-26-01908">20</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Assess neoadjuvant therapy efficacy</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atezolizumab + Docetaxel + Trastuzumab + Pertuzumab</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pathologic complete response: 61%</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc">
<li><p>Febrile neutropenia</p></li>
<li><p>Encephalitis</p></li>
</ul>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B21-ijms-26-01908" class="usa-link" aria-describedby="B21-ijms-26-01908">21</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">329</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compare Pertuzumab vs. placebo in early BC</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab + Trastuzumab + Docetaxel vs. Placebo</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Higher pathologic response in the Pertuzumab group</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc"><li><p>Neutropenia</p></li></ul>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B22-ijms-26-01908" class="usa-link" aria-describedby="B22-ijms-26-01908">22</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1436</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Assess the safety and tolerability of combination therapy</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab + Trastuzumab + Taxane</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median PFS: 20.7 months</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc">
<li><p>Neutropenia </p></li>
<li><p>Diarrhea</p></li>
</ul>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B23-ijms-26-01908" class="usa-link" aria-describedby="B23-ijms-26-01908">23</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4085</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluate disease-free survival in an adjuvant setting</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab + Trastuzumab + Chemotherapy vs. Placebo</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improved 3-year disease-free survival</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc"><li><p>Diarrhea</p></li></ul>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B24-ijms-26-01908" class="usa-link" aria-describedby="B24-ijms-26-01908">24</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">276</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Assess the safety of subcutaneous Trastuzumab</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous Trastuzumab + Pertuzumab + Docetaxel</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median PFS: 18.7 months</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc">
<li><p>Neutropenia </p></li>
<li><p>Hypertension</p></li>
</ul>
</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B25-ijms-26-01908" class="usa-link" aria-describedby="B25-ijms-26-01908">25</a>]</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">268</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Analyze the real-world efficacy of Pertuzumab combinations</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Various combinations including Pertuzumab</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Median OS: 19.1 months</td>
<td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="list" style="list-style-type:disc"><li><p>Variable, consistent with CLEOPATRA</p></li></ul>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/ijms-26-01908-t002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>In the treatment of HER2-positive breast cancer, recent research has demonstrated the efficacy of therapeutic combinations including pertuzumab and trastuzumab in various clinical settings, as well as a favorable safety profile in various populations. The phase III KRISTINE trial compared neoadjuvant treatment with trastuzumab emtasine and pertuzumab with a combination of docetaxel, carboplatin, trastuzumab, and pertuzumab. The results showed a complete pathologic response rate of 44.4% in the first group and 55.7% in the second, with adverse events including plateletopenia and fatigue in the em-tasine group and neutropenia and diarrhea in the trastuzumab and pertuzumab chemo-therapy group, with these effects being more frequent in the latter group [<a href="#B14-ijms-26-01908" class="usa-link" aria-describedby="B14-ijms-26-01908">14</a>].</p>
<p>In the PERTAIN trial, patients with HER2-positive, hormone-receptor-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and an aromatase inhibitor showed a median progression-free survival of 18.89 months compared to 15.80 months with trastuzumab alone. The combination therapy demonstrated a safety profile consistent with previous studies, with the most common adverse events being diarrhea, alopecia, and nausea, while left ventricular ejection fraction remained stable in most patients [<a href="#B15-ijms-26-01908" class="usa-link" aria-describedby="B15-ijms-26-01908">15</a>].</p>
<p>The DESTINY-Breast03 trial demonstrated that trastuzumab deruxtecan achieved a median progression-free survival of 29.1 months, outperforming trastuzumab emtasine at 7.2 months. In addition, trastuzumab deruxtecan showed a significant benefit in overall survival, although adverse events such as pneumonitis and pneumonia necessitated the discontinuation of treatment in some cases [<a href="#B16-ijms-26-01908" class="usa-link" aria-describedby="B16-ijms-26-01908">16</a>].</p>
<p>The PUFFIN study, conducted in Chinese patients with HER2-positive breast cancer, reported a median progression-free survival of 16.5 months with Pertuzumab compared to 12.5 months in the placebo group. Safety and efficacy results were consistent with the CLEOPATRA study, with leukopenia being the most common adverse event [<a href="#B17-ijms-26-01908" class="usa-link" aria-describedby="B17-ijms-26-01908">17</a>]. On the other hand, the MARIANNE trial evaluated trastuzumab emtasine, both as monotherapy and in combination with pertuzumab, versus trastuzumab plus taxane in patients with HER2-positive advanced breast cancer. The results showed that trastuzumab emtasine and its combination with pertuzumab were not superior to trastuzumab and taxane in terms of progression-free survival, although they had a lower incidence of serious adverse events such as alopecia and diarrhea compared to the control treatment [<a href="#B18-ijms-26-01908" class="usa-link" aria-describedby="B18-ijms-26-01908">18</a>].</p>
<p>The Chinese subgroup of the APHINITY trial evaluated the adjuvant use of pertuzumab in combination with trastuzumab and standard chemotherapy and demonstrated greater efficacy and a safety profile consistent with the overall population. The most common adverse events were diarrhea and febrile neutropenia, and no serious cardiac events were observed in this group [<a href="#B19-ijms-26-01908" class="usa-link" aria-describedby="B19-ijms-26-01908">19</a>]. In the Neo-PATH trial, which evaluated the combination of atezolizumab, docetaxel, trastuzumab, and pertuzumab in patients with stage II or III HER2-positive breast cancer, a pathologic complete response rate of 61% was achieved, with a higher response rate in hormone receptor-negative (77%) compared to hormone receptor-positive (44%) patients. The most common adverse events were febrile neutropenia and encephalitis [<a href="#B20-ijms-26-01908" class="usa-link" aria-describedby="B20-ijms-26-01908">20</a>].</p>
<p>The PEONY study reported a pathologic complete response rate of 39.3% in the per-tuzumab group versus 21.8% in the placebo group, showing a significant improvement with treatment. Adverse events such as neutropenia were more common in the pertuzumab group [<a href="#B21-ijms-26-01908" class="usa-link" aria-describedby="B21-ijms-26-01908">21</a>]. In addition, the PERUSE trial, which included patients with HER2-positive, hormone-receptor-positive breast cancer, showed a median progression-free survival of 20.7 months and overall survival of more than five years in this group, supporting the safety and efficacy of the combination of pertuzumab, trastuzumab, and a tax-ane, consistent with the results of the CLEOPATRA trial [<a href="#B22-ijms-26-01908" class="usa-link" aria-describedby="B22-ijms-26-01908">22</a>].</p>
<p>In a prospective multinational trial evaluating the combination of pertuzumab and trastuzumab with adjuvant chemotherapy, an improvement in 3-year disease-free survival was observed in patients with HER2-positive breast cancer, especially in those with positive nodes, although no significant differences were found in node-negative patients. Diarrhea was the most common adverse event in the pertuzumab group [<a href="#B23-ijms-26-01908" class="usa-link" aria-describedby="B23-ijms-26-01908">23</a>]. Finally, the MetaPHER trial confirmed the efficacy of subcutaneous trastuzumab in combination with pertuzumab and docetaxel in patients with HER2-positive breast cancer, with a progres-sion-free survival of 18.7 months and adverse events such as neutropenia and hypertension, suggesting greater flexibility in patient management [<a href="#B24-ijms-26-01908" class="usa-link" aria-describedby="B24-ijms-26-01908">24</a>].</p>
<p>Taken together, these studies support the use of pertuzumab and trastuzumab in combination to improve progression-free survival and overall survival in patients with HER2-positive breast cancer, while maintaining a favorable safety profile compared to standard of care. The following is a summary of the major clinical trials that evaluated combination therapies in patients with HER2-positive breast cancer, highlighting the efficacy and most common adverse events associated with the therapies. The table summarizes key data from each trial, including progression-free survival, pathologic complete response, overall survival, and the most common adverse events observed in the different treatment groups. These studies provide evidence on the efficacy of various therapeutic combinations, such as trastuzumab, pertuzumab, and trastuzumab deruxtecan, compared to standard of care and placebo, and help guide clinical decisions in the treatment of HER2-positive breast cancer. The results are presented in separate sections for neoadjuvant, adjuvant, and metastatic settings to ensure a clear understanding of the efficacy and safety of pertuzumab-based regimens within each clinical context (<a href="#ijms-26-01908-t003" class="usa-link">Table 3</a>).</p>
<section class="tw xbox font-sm" id="ijms-26-01908-t003"><h3 class="obj_head">Table 3.</h3>
<div class="caption p"><p>Summary of clinical trials evaluating the combination of pertuzumab, trastuzumab, and other therapies in HER2-positive breast cancer.</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Context</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Treatment</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PFS (Months)</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PCR (%)</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">OS (Months)</th>
<th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Common AE</th>
</tr></thead>
<tbody>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">KRISTINE</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive breast cancer, neoadjuvant setting</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trastuzumab emtasina + Pertuzumab vs. Docetaxel + carboplatin + Trastuzumab + Pertuzumab</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.4% (emtasine) vs. 55.7% (chemotherapy)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thrombocytopenia, fatigue (emtansine); neutropenia, diarrhea (chemotherapy</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PERTAIN</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive metastatic breast cancer, hormone receptor-positive.</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab + trastuzumab + aromatase inhibitor vs. trastuzumab alone</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.89 (com-bination) vs. 15.80 (Trastuzumab)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diarrhea, alopecia, nausea; stable ejection fraction</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DESTINY-Breast03</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced HER2-positive breast cancer</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trastuzumab deruxtecan vs. Trastuzumab emtasine</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29.1 (derux-tecan) vs. 7.2 (emtasine)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Significant improvement in deruxtecan</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pneumonitis, neu-monia (treatment interrupted in some cases)</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PUFFIN</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive breast cancer, Chinese patients</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab vs. placebo</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.5 (pertuzumab) vs. 12.5 (placebo)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leukopenia</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MARIANNE</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive advanced breast cancer</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trastuzumab emtasine (alone or with Pertuzumab) vs. Trastuzumab + taxane</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not superior to Trastuzumab + taxane</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Less alopecia and diarrhea in emtasin than in Trastuzumab + taxane.</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">APHINITY (China)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive breast cancer, adjuvant use</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab + Trastuzumab + standard chemotherapy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diarrhea, febrile neutropenia; no serious cardiac events</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neo-PATH</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive breast cancer stages II-III</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atezolizumab + Docetaxel + Trastuzumab + Pertuzumab</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">61% (overall); 77% (negative HR) vs. 44% (positive HR)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Febrile neutropenia, encephalitis</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEONY</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive breast cancer</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab vs. placebo</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39.3% (Per-tuzumab) vs. 21.8% (placebo)</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutropenia (frequent in the Pertuzumab group)</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PERUSE</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive and hormone receptor-positive breast cancer</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab + Trastuzumab + taxane</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20.7</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;60 months</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Consistent safety and efficacy; CLEOPATRA-aligned results</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant assay</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive breast cancer, adjuvant use</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab + Trastuzumab + chemotherapy</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diarrhea (frequent in the Pertuzumab group)</td>
</tr>
<tr>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MetaPHER</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive breast cancer</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subcutaneous Trastuzumab + Pertuzumab + Docetaxel</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18.7</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
<td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutropenia, hypertension</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/ijms-26-01908-t003/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn2"><p>PFS: progression-free survival; PCR: pathologic complete response; OS: overall survival.</p></div></div></section><p>The heterogeneity in study populations and endpoints posed challenges for direct comparisons. However, by stratifying the evidence and focusing on consistent measures such as progression-free survival and toxicity profiles, we provide a comprehensive synthesis that informs clinical decision-making. HER2-positive breast cancer (HER2+ BC) has become one of the leading causes of morbidity and mortality in women worldwide, particularly those between the ages of 20 and 59. This form of cancer represents a clinically relevant subtype of breast pathology characterized by overexpression of the HER2 receptor and its involvement in tumor aggressiveness. Historically, the first-line treatment for HER2+ BC has been chemotherapy; however, the development of targeted therapies has significantly changed the treatment approach in recent years, allowing the integration of drugs such as trastuzumab and pertuzumab with chemotherapeutic agents such as docetaxel. This systematic review is based on a comprehensive analysis of recent studies and examines the benefits and potential adverse effects of this therapeutic combination compared with conventional options.</p>
<p>In the 2020 CLEOPATRA study, a randomized phase III trial, Swain et al. investigated the combination of pertuzumab, Trastuzumab, and Docetaxel compared to a treatment without pertuzumab. The findings showed a significant improvement in progression-free survival and overall survival in the group treated with the triple combination [<a href="#B11-ijms-26-01908" class="usa-link" aria-describedby="B11-ijms-26-01908">11</a>]. </p>
<p>These results are consistent with those reported by Nicholas J. Rober et al. [<a href="#B12-ijms-26-01908" class="usa-link" aria-describedby="B12-ijms-26-01908">12</a>], who approved the use of pertuzumab in combination with Trastuzumab and Docetaxel in patients without prior chemotherapy, observing a median progression-free survival of 16.9 months. In addition, the study by Vázquez et al. [<a href="#B13-ijms-26-01908" class="usa-link" aria-describedby="B13-ijms-26-01908">13</a>] compared Paclitaxel dual therapy with dual therapy versus Paclitaxel plus Trastuzumab, again finding a significant improvement in survival and clinical tumor response.</p>
<p>The KRISTINE trial by Hurvitz et al. [<a href="#B14-ijms-26-01908" class="usa-link" aria-describedby="B14-ijms-26-01908">14</a>], which included pertuzumab, trastuzumab, and docetaxel along with carboplatin, also demonstrated an increase in pathologic response. In a more recent study, DESTINY-Breast03, the same author demonstrated that trastuzumab deruxtecan showed a progression-free survival of 29.1 months compared to 7.2 months achieved with trastuzumab emtasine [<a href="#B16-ijms-26-01908" class="usa-link" aria-describedby="B16-ijms-26-01908">16</a>]. For its part, the PERTAIN study by Mothaffar Rimawi et al. [<a href="#B16-ijms-26-01908" class="usa-link" aria-describedby="B16-ijms-26-01908">16</a>] reaffirmed the safety of the dual therapy and reported a median survival of 18.89 months in the pertuzumab group versus 15.80 months in the group treated with trastuzumab alone. The PUFFIN trial conducted in China by Binghe Xu et al. [<a href="#B17-ijms-26-01908" class="usa-link" aria-describedby="B17-ijms-26-01908">17</a>] showed results consistent with the CLEOPATRA trial in terms of the efficacy of triple therapy, consolidating the benefit of pertuzumab in combination with trastuzumab and docetaxel in terms of risk-benefit.</p>
<p>Additional studies, such as MARIANNE [<a href="#B18-ijms-26-01908" class="usa-link" aria-describedby="B18-ijms-26-01908">18</a>] by Edith Perez et al. which included a taxane, and PEONY by Zhimin Shao et al. [<a href="#B21-ijms-26-01908" class="usa-link" aria-describedby="B21-ijms-26-01908">21</a>] support these findings, highlighting an improvement in complete pathologic response in the group treated with pertuzumab, trastuzumab, and docetaxel. Similarly, the subset of the APHINITY trial conducted by Zhimin Shao et al. [<a href="#B19-ijms-26-01908" class="usa-link" aria-describedby="B19-ijms-26-01908">19</a>,<a href="#B20-ijms-26-01908" class="usa-link" aria-describedby="B20-ijms-26-01908">20</a>] highlighted the efficacy of adding pertuzumab as adjuvant therapy after surgery in patients with HER2+ early CM [<a href="#B19-ijms-26-01908" class="usa-link" aria-describedby="B19-ijms-26-01908">19</a>]. In smaller studies, such as the phase II study by Ahn et al. [<a href="#B20-ijms-26-01908" class="usa-link" aria-describedby="B20-ijms-26-01908">20</a>], the combination of pertuzumab, trastuzumab, docetaxel, and atezolizumab reported a pathologic complete response rate of 61%.</p>
<p>At the safety level, adverse effects (AEs) associated with pertuzumab in combination with trastuzumab and chemotherapy include symptoms such as diarrhea, fatigue, nausea, and peripheral neutropenia, as observed in the study by Nicholas J. Rober et al. [<a href="#B12-ijms-26-01908" class="usa-link" aria-describedby="B12-ijms-26-01908">12</a>]. Recent studies such as PUFFIN (2022) and PERTAIN (2018) also identified diarrhea, alopecia, and leukopenia as the most common adverse events [<a href="#B15-ijms-26-01908" class="usa-link" aria-describedby="B15-ijms-26-01908">15</a>,<a href="#B17-ijms-26-01908" class="usa-link" aria-describedby="B17-ijms-26-01908">17</a>]. Regarding cardiac function, several studies, including MetaPHER by Kuemmel et al. [<a href="#B23-ijms-26-01908" class="usa-link" aria-describedby="B23-ijms-26-01908">23</a>] and the study by Minckwitz et al. [<a href="#B24-ijms-26-01908" class="usa-link" aria-describedby="B24-ijms-26-01908">24</a>], reported a stable left ventricular ejection fraction (LVEF), albeit with a higher incidence of diarrhea and other AEs in the pertuzumab group.</p>
<p>Other studies include the PERUSE trial by Millas et al. [<a href="#B22-ijms-26-01908" class="usa-link" aria-describedby="B22-ijms-26-01908">22</a>], which confirmed the safety and tolerability of combination therapy, and the retrospective study by Young Pio Lee et al. [<a href="#B25-ijms-26-01908" class="usa-link" aria-describedby="B25-ijms-26-01908">25</a>], which reported an overall response rate of 86.8% in patients with previously un-treated metastatic disease. Subcutaneous administration of trastuzumab, as evaluated by Kuemmel et al. in MetaPHER, was found to be an effective and safe option, providing additional flexibility for patients [<a href="#B24-ijms-26-01908" class="usa-link" aria-describedby="B24-ijms-26-01908">24</a>]. In conclusion, current evidence suggests that the combination of pertuzumab, trastuzumab, and chemotherapy in the treatment of HER2+ CM offers clear benefits in terms of survival and clinical response. However, the adverse event profile, particularly neutropenia and diarrhea, requires appropriate monitoring to optimize patient safety and treatment efficacy. These findings re-emphasize the potential of combination regimens as a first-line option in HER2+ CM and suggest their inclusion in clinical guidelines, particularly for patients at high risk of relapse.</p>
<p>This review makes a unique contribution by systematically evaluating the efficacy and safety of the combination of pertuzumab, trastuzumab, and docetaxel in different clinical settings. In contrast to previous reviews, this study integrates results from recent clinical trials and highlights the differences in treatment response in different patient populations. By providing a structured comparison of key studies, this review advances the current understanding of dual HER2 blockade and its role in optimizing treatment strategies for HER2-positive breast cancer.</p>
<p>This review highlights the potential impact of combining pertuzumab and trastuzumab with chemotherapy on future breast cancer research. By synthesizing data from multiple clinical trials, this analysis identifies gaps in current knowledge and underscores the need for further investigation to optimize treatment regimens, understand long-term safety profiles, and explore novel therapeutic combinations. Future studies should focus on refining patient selection criteria and evaluating real-world outcomes to ensure that this therapeutic approach benefits a broader range of patients with HER2-positive breast cancer.</p></section><section id="sec4-ijms-26-01908"><h2 class="pmc_sec_title">4. Conclusions</h2>
<p>This systematic review highlights the clinical efficacy and safety of combining pertuzumab, trastuzumab, and docetaxel across different treatment settings for HER2-positive breast cancer, including neoadjuvant, adjuvant, and metastatic contexts. While the heterogeneity of patient populations, endpoints, and study designs poses challenges for direct comparisons, this diversity also reflects the versatility of this combination therapy in addressing various clinical needs. To provide clearer insights, we categorized the included studies based on treatment intent (neoadjuvant, adjuvant, or metastatic), outcome measures (progression-free survival, overall survival, or pathologic complete response), and toxicity profiles. This structured approach allows for a more nuanced understanding of the therapeutic potential and limitations of pertuzumab-based regimens, emphasizing their role as a cornerstone in the treatment of HER2-positive breast cancer. Advances in the treatment of HER2-positive breast cancer underscore the efficacy of the combination of pertuzumab, trastuzumab, and docetaxel, which has demonstrated a significant improvement in disease-free survival over conventional treatment. However, this combination therapy is not without side effects, with neutropenia and diarrhea being the most common adverse events. Careful consideration of these risks by healthcare professionals is essential to optimize treatment planning and follow-up. In addition, adjuvant dual therapy with pertuzumab and trastuzumab appears to be a promising first-line option, especially for patients at high risk of recurrence, suggesting an important step towards more effective and personalized treatments in oncology. Future studies should focus on standardizing endpoints and treatment protocols across settings to further refine the role of pertuzumab in HER2-positive breast cancer management.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>The authors thank the Catholic University of Valencia San Vicente Mártir for their contribution and help in the payment of the Open Access publication fee.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<p>The following abbreviations are used in this manuscript:
</p>
<section class="tw xbox font-sm" id="array1"><div class="tbl-box p" tabindex="0"><table class="content">
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">ADC</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Antibody–Drug Conjugate</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">BC</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Breast Cancer</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">ER</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Estrogen Receptor</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">HER2</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Human Epidermal Growth Factor Receptor 2</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">OS</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Overall Survival</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">PCR</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Pathologic Complete Response</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">PFS</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Progression-Free Survival</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">PR</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Progesterone Receptor</td>
</tr>
<tr>
<td align="left" valign="middle" rowspan="1" colspan="1">TNBC</td>
<td align="left" valign="middle" rowspan="1" colspan="1">Triple Negative Breast Cancer</td>
</tr>
</table></div>
<div class="p text-right font-secondary"><a href="table/array1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="app1-ijms-26-01908" class="app"><h2 class="pmc_sec_title">Supplementary Materials</h2>
<p>The following supporting information can be downloaded at: <a href="https://www.mdpi.com/article/10.3390/ijms26051908/s1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.mdpi.com/article/10.3390/ijms26051908/s1</a>. </p>
<section class="sm xbox font-sm" id="ijms-26-01908-s001"><div class="media p"><div class="caption">
<a href="/articles/instance/11899880/bin/ijms-26-01908-s001.zip" data-ga-action="click_feat_suppl" class="usa-link">ijms-26-01908-s001.zip</a><sup> (108.8KB, zip) </sup>
</div></div></section></section><section id="notes1"><h2 class="pmc_sec_title">Author Contributions</h2>
<p>Conceptualization, I.V. and N.P.S.; methodology, M.P.-B., M.E.L.-G. and M.T.M.-L.; validation, I.V. and M.P.-B.; investigation, N.P.S., J.P.-M., M.T.-A., F.T.-A.; writing—original draft preparation, I.V., N.P.S., M.P.-B., J.P.-M., M.T.-A., F.T.-A., M.E.L.-G. and M.T.M.-L.; writing—review and editing, M.P.-B., J.P.-M., M.T.-A., F.T.-A., M.E.L.-G. and M.T.M.-L.; supervision, I.V.; All authors have read and agreed to the published version of the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>No new data were created or analyzed in this study.</p></section><section id="notes3"><h2 class="pmc_sec_title">Conflicts of Interest</h2>
<p>The authors declare no conflicts of interest.</p></section><section id="funding-statement1" lang="en"><h2 class="pmc_sec_title">Funding Statement</h2>
<p>This research received no external funding.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1"><p><strong>Disclaimer/Publisher’s Note:</strong> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></div></div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="B1-ijms-26-01908">
<span class="label">1.</span><cite>Aranda-Gutierrez A., Diaz-Perez H.M.  StatPearls [Internet] StatPearls Publishing; Treasure Island, FL, USA: 2024. Histology, Mammary Glands. 2023 May 1.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/31613512/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?title=StatPearls%20%5BInternet%5D&amp;author=A.%20Aranda-Gutierrez&amp;author=H.M.%20Diaz-Perez&amp;publication_year=2024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B2-ijms-26-01908">
<span class="label">2.</span><cite>Chen Y.F., Xu Y.Y., Shao Z.M., Yu K.D. Resistance to antibody-drug conjugates in breast cancer: Mechanisms and solutions. Cancer Commun. 2023;43:297–337. doi: 10.1002/cac2.12387.</cite> [<a href="https://doi.org/10.1002/cac2.12387" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10009672/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36357174/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Commun.&amp;title=Resistance%20to%20antibody-drug%20conjugates%20in%20breast%20cancer:%20Mechanisms%20and%20solutions&amp;author=Y.F.%20Chen&amp;author=Y.Y.%20Xu&amp;author=Z.M.%20Shao&amp;author=K.D.%20Yu&amp;volume=43&amp;publication_year=2023&amp;pages=297-337&amp;pmid=36357174&amp;doi=10.1002/cac2.12387&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B3-ijms-26-01908">
<span class="label">3.</span><cite>Orrantia-Borunda E., Anchondo-Nuñez P., Acuña-Aguilar L.E., Gómez-Valles F.O., Ramírez-Valdespino C.A.  Subtypes of Breast Cancer. In: Mayrovitz H.N., editor. Breast Cancer [Internet] Exon Publications; Brisbane, Australia: Aug 6, 2022. </cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/36122153/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?title=Breast%20Cancer%20%5BInternet%5D&amp;author=E.%20Orrantia-Borunda&amp;author=P.%20Anchondo-Nu%C3%B1ez&amp;author=L.E.%20Acu%C3%B1a-Aguilar&amp;author=F.O.%20G%C3%B3mez-Valles&amp;author=C.A.%20Ram%C3%ADrez-Valdespino&amp;publication_year=2022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B4-ijms-26-01908">
<span class="label">4.</span><cite>Alkabban F.M., Ferguson T.  StatPearls [Internet] StatPearls Publishing; Treasure Island, FL, USA: 2024. Breast Cancer. [Updated 2022 Sep 26]</cite> [<a href="https://scholar.google.com/scholar_lookup?title=StatPearls%20%5BInternet%5D&amp;author=F.M.%20Alkabban&amp;author=T.%20Ferguson&amp;publication_year=2024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B5-ijms-26-01908">
<span class="label">5.</span><cite>Trayes K.P., Cokenakes S.E.H. Breast Cancer Treatment. Am. Fam. Physician. 2021;104:171–178.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/34383430/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am.%20Fam.%20Physician&amp;title=Breast%20Cancer%20Treatment&amp;author=K.P.%20Trayes&amp;author=S.E.H.%20Cokenakes&amp;volume=104&amp;publication_year=2021&amp;pages=171-178&amp;pmid=34383430&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B6-ijms-26-01908">
<span class="label">6.</span><cite>Arzanova E., Mayrovitz H.N.  The Epidemiology of Breast Cancer. In: Mayrovitz H.N., editor. Breast Cancer [Internet] Exon Publications; Brisbane, Australia: Aug 6, 2022.  Chapter 1.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/36122161/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?title=Breast%20Cancer%20%5BInternet%5D&amp;author=E.%20Arzanova&amp;author=H.N.%20Mayrovitz&amp;publication_year=2022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B7-ijms-26-01908">
<span class="label">7.</span><cite>White M.C., Holman D.M., Boehm J.E., Peipins L.A., Grossman M., Henley S.J. Age and cancer risk: A potentially modifiable relationship. Am. J. Prev. Med. 2014;46((Suppl. S1)):S7–S15. doi: 10.1016/j.amepre.2013.10.029.</cite> [<a href="https://doi.org/10.1016/j.amepre.2013.10.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4544764/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24512933/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am.%20J.%20Prev.%20Med.&amp;title=Age%20and%20cancer%20risk:%20A%20potentially%20modifiable%20relationship&amp;author=M.C.%20White&amp;author=D.M.%20Holman&amp;author=J.E.%20Boehm&amp;author=L.A.%20Peipins&amp;author=M.%20Grossman&amp;volume=46&amp;issue=(Suppl.%20S1)&amp;publication_year=2014&amp;pages=S7-S15&amp;pmid=24512933&amp;doi=10.1016/j.amepre.2013.10.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B8-ijms-26-01908">
<span class="label">8.</span><cite>Admoun C., Mayrovitz H.N.  The Etiology of Breast Cancer. In: Mayrovitz H.N., editor. Breast Cancer [Internet] Exon Publications; Brisbane, Australia: Aug 6, 2022.  Chapter 2.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/36122154/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?title=Breast%20Cancer%20%5BInternet%5D&amp;author=C.%20Admoun&amp;author=H.N.%20Mayrovitz&amp;publication_year=2022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B9-ijms-26-01908">
<span class="label">9.</span><cite>Liberati A., Altman D.G., Tetzlaff J., Mulrow C., Gøtzsche P.C., Ioannidis J.P., Clarke M., Devereaux P.J., Kleijnen J., Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ. 2009;339:b2700. doi: 10.1136/bmj.b2700.</cite> [<a href="https://doi.org/10.1136/bmj.b2700" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2714672/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19622552/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=The%20PRISMA%20statement%20for%20reporting%20systematic%20reviews%20and%20meta-analyses%20of%20studies%20that%20evaluate%20healthcare%20interventions:%20Explanation%20and%20elaboration&amp;author=A.%20Liberati&amp;author=D.G.%20Altman&amp;author=J.%20Tetzlaff&amp;author=C.%20Mulrow&amp;author=P.C.%20G%C3%B8tzsche&amp;volume=339&amp;publication_year=2009&amp;pages=b2700&amp;pmid=19622552&amp;doi=10.1136/bmj.b2700&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B10-ijms-26-01908">
<span class="label">10.</span><cite>Jordan Z., Lockwood C., Munn Z., Aromataris E. The updated Joanna Briggs Institute Model of Evidence-Based Healthcare. Int. J. Evid. Based Healthc. 2019;17:58–71. doi: 10.1097/XEB.0000000000000155.</cite> [<a href="https://doi.org/10.1097/XEB.0000000000000155" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30256247/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Evid.%20Based%20Healthc.&amp;title=The%20updated%20Joanna%20Briggs%20Institute%20Model%20of%20Evidence-Based%20Healthcare&amp;author=Z.%20Jordan&amp;author=C.%20Lockwood&amp;author=Z.%20Munn&amp;author=E.%20Aromataris&amp;volume=17&amp;publication_year=2019&amp;pages=58-71&amp;pmid=30256247&amp;doi=10.1097/XEB.0000000000000155&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B11-ijms-26-01908">
<span class="label">11.</span><cite>Swain S.M., Miles D., Kim S.B., Im Y.H., Im S.A., Semiglazov V., Ciruelos E., Schneeweiss A., Loi S., Monturus E., et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:519–530. doi: 10.1016/S1470-2045(19)30863-0.</cite> [<a href="https://doi.org/10.1016/S1470-2045(19)30863-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32171426/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&amp;title=Pertuzumab,%20trastuzumab,%20and%20docetaxel%20for%20HER2-positive%20metastatic%20breast%20cancer%20(CLEOPATRA):%20End-of-study%20results%20from%20a%20double-blind,%20randomised,%20placebo-controlled,%20phase%203%20study&amp;author=S.M.%20Swain&amp;author=D.%20Miles&amp;author=S.B.%20Kim&amp;author=Y.H.%20Im&amp;author=S.A.%20Im&amp;volume=21&amp;publication_year=2020&amp;pages=519-530&amp;pmid=32171426&amp;doi=10.1016/S1470-2045(19)30863-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B12-ijms-26-01908">
<span class="label">12.</span><cite>Robert N.J., Goertz H.P., Chopra P., Jiao X., Yoo B., Patt D., Antao V. HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes. Drugs Real World Outcomes. 2017;4:1–7. doi: 10.1007/s40801-016-0102-5.</cite> [<a href="https://doi.org/10.1007/s40801-016-0102-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5332306/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28063028/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drugs%20Real%20World%20Outcomes&amp;title=HER2-Positive%20Metastatic%20Breast%20Cancer%20Patients%20Receiving%20Pertuzumab%20in%20a%20Community%20Oncology%20Practice%20Setting:%20Treatment%20Patterns%20and%20Outcomes&amp;author=N.J.%20Robert&amp;author=H.P.%20Goertz&amp;author=P.%20Chopra&amp;author=X.%20Jiao&amp;author=B.%20Yoo&amp;volume=4&amp;publication_year=2017&amp;pages=1-7&amp;pmid=28063028&amp;doi=10.1007/s40801-016-0102-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B13-ijms-26-01908">
<span class="label">13.</span><cite>Vazquez J.C., Antolin S., Ruiz-Borrego M., Servitja S., Alba E., Barnadas A., Lluch A., Martin M., Rodriguez-Lescure A., Sola I., et al.  Dual neoadjuvant blockade plus chemotherapy versus monotherapy for the 74 treatment of women with non-metastatic HER2-positive breast cancer: A systematic review and meta-analysis. Clin. Transl. Oncol. 2023;25:941–958. doi: 10.1007/s12094-022-02998-2.</cite> [<a href="https://doi.org/10.1007/s12094-022-02998-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36417083/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Transl.%20Oncol.&amp;title=Dual%20neoadjuvant%20blockade%20plus%20chemotherapy%20versus%20monotherapy%20for%20the%2074%20treatment%20of%20women%20with%20non-metastatic%20HER2-positive%20breast%20cancer:%20A%20systematic%20review%20and%20meta-analysis&amp;author=J.C.%20Vazquez&amp;author=S.%20Antolin&amp;author=M.%20Ruiz-Borrego&amp;author=S.%20Servitja&amp;author=E.%20Alba&amp;volume=25&amp;publication_year=2023&amp;pages=941-958&amp;pmid=36417083&amp;doi=10.1007/s12094-022-02998-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B14-ijms-26-01908">
<span class="label">14.</span><cite>Hurvitz S.A., Martin M., Symmans W.F., Jung K.H., Huang C.S., Thompson A.M., Harbeck N., Valero V., Stroyakovskiy D., Wildiers H., et al.  Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018;19:115–126. doi: 10.1016/S1470-2045(17)30716-7.</cite> [<a href="https://doi.org/10.1016/S1470-2045(17)30716-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29175149/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Oncol.&amp;title=Neoadjuvant%20trastuzumab,%20pertuzumab,%20and%20chemotherapy%20versus%20trastuzumab%20emtansine%20plus%20pertuzumab%20in%20patients%20with%20HER2-positive%20breast%20cancer%20(KRISTINE):%20A%20randomised,%20open-label,%20multicentre,%20phase%203%20trial&amp;author=S.A.%20Hurvitz&amp;author=M.%20Martin&amp;author=W.F.%20Symmans&amp;author=K.H.%20Jung&amp;author=C.S.%20Huang&amp;volume=19&amp;publication_year=2018&amp;pages=115-126&amp;pmid=29175149&amp;doi=10.1016/S1470-2045(17)30716-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B15-ijms-26-01908">
<span class="label">15.</span><cite>Rimawi M., Ferrero J.M., de la Haba-Rodriguez J., Poole C., De Placido S., Osborne C.K., Hegg R., Easton V., Wohlfarth C., Arpino G., et al.  FirstLine Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone ReceptorPositive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. J. Clin. Oncol. 2018;36:2826–2835. doi: 10.1200/JCO.2017.76.7863.</cite> [<a href="https://doi.org/10.1200/JCO.2017.76.7863" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30106636/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=FirstLine%20Trastuzumab%20Plus%20an%20Aromatase%20Inhibitor,%20With%20or%20Without%20Pertuzumab,%20in%20Human%20Epidermal%20Growth%20Factor%20Receptor%202-Positive%20and%20Hormone%20ReceptorPositive%20Metastatic%20or%20Locally%20Advanced%20Breast%20Cancer%20(PERTAIN):%20A%20Randomized,%20Open-Label%20Phase%20II%20Trial&amp;author=M.%20Rimawi&amp;author=J.M.%20Ferrero&amp;author=J.%20de%20la%20Haba-Rodriguez&amp;author=C.%20Poole&amp;author=S.%20De%20Placido&amp;volume=36&amp;publication_year=2018&amp;pages=2826-2835&amp;pmid=30106636&amp;doi=10.1200/JCO.2017.76.7863&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B16-ijms-26-01908">
<span class="label">16.</span><cite>Hurvitz S.A., Hegg R., Chung W.P., Im S.A., Jacot W., Ganju V., Chiu J.W.Y., Xu B., Hamilton E., Madhusudan S., et al.  Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-75 Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401:105–117. doi: 10.1016/S0140-6736(22)02420-5.</cite> [<a href="https://doi.org/10.1016/S0140-6736(22)02420-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36495879/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Trastuzumab%20deruxtecan%20versus%20trastuzumab%20emtansine%20in%20patients%20with%20HER2-positive%20metastatic%20breast%20cancer:%20Updated%20results%20from%20DESTINY-75%20Breast03,%20a%20randomised,%20open-label,%20phase%203%20trial&amp;author=S.A.%20Hurvitz&amp;author=R.%20Hegg&amp;author=W.P.%20Chung&amp;author=S.A.%20Im&amp;author=W.%20Jacot&amp;volume=401&amp;publication_year=2023&amp;pages=105-117&amp;pmid=36495879&amp;doi=10.1016/S0140-6736(22)02420-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B17-ijms-26-01908">
<span class="label">17.</span><cite>Xu B., Li W., Zhang Q., Li Q., Wang X., Li H., Sun T., Yin Y., Zheng H., Feng J., et al.  Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): Final analysis of a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res. Treat. 2023;197:503–513. doi: 10.1007/s10549-022-06775-1.</cite> [<a href="https://doi.org/10.1007/s10549-022-06775-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9883304/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36463547/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Breast%20Cancer%20Res.%20Treat.&amp;title=Pertuzumab,%20trastuzumab,%20and%20docetaxel%20for%20Chinese%20patients%20with%20previously%20untreated%20HER2-positive%20locally%20recurrent%20or%20metastatic%20breast%20cancer%20(PUFFIN):%20Final%20analysis%20of%20a%20phase%20III,%20randomized,%20double-blind,%20placebo-controlled%20study&amp;author=B.%20Xu&amp;author=W.%20Li&amp;author=Q.%20Zhang&amp;author=Q.%20Li&amp;author=X.%20Wang&amp;volume=197&amp;publication_year=2023&amp;pages=503-513&amp;pmid=36463547&amp;doi=10.1007/s10549-022-06775-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B18-ijms-26-01908">
<span class="label">18.</span><cite>Perez E.A., Barrios C., Eiermann W., Toi M., Im Y.H., Conte P., Martin M., Pienkowski T., Pivot X., Burris H., 3rd, et al.  Trastuzumab Emtansine with or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study. J. Clin. Oncol. 2017;35:141–148. doi: 10.1200/JCO.2016.67.4887.</cite> [<a href="https://doi.org/10.1200/JCO.2016.67.4887" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5455677/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28056202/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Trastuzumab%20Emtansine%20with%20or%20Without%20Pertuzumab%20Versus%20Trastuzumab%20Plus%20Taxane%20for%20Human%20Epidermal%20Growth%20Factor%20Receptor%202-Positive,%20Advanced%20Breast%20Cancer:%20Primary%20Results%20From%20the%20Phase%20III%20MARIANNE%20Study&amp;author=E.A.%20Perez&amp;author=C.%20Barrios&amp;author=W.%20Eiermann&amp;author=M.%20Toi&amp;author=Y.H.%20Im&amp;volume=35&amp;publication_year=2017&amp;pages=141-148&amp;pmid=28056202&amp;doi=10.1200/JCO.2016.67.4887&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B19-ijms-26-01908">
<span class="label">19.</span><cite>Shao Z., Tseng L.-M., Huang C.-S., Pang D., Yang Y., Li W., Liao N., Geng C., Zhang Q., Xu B., et al.  Pertuzumab and trastuzumab as adjuvant treatment for HER2-positive early breast cancer: Outcomes in Chinese patients in the APHINITY study. Jpn. J. Clin. Oncol. 2021;51:345–353. doi: 10.1093/jjco/hyaa216.</cite> [<a href="https://doi.org/10.1093/jjco/hyaa216" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33619550/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Jpn.%20J.%20Clin.%20Oncol.&amp;title=Pertuzumab%20and%20trastuzumab%20as%20adjuvant%20treatment%20for%20HER2-positive%20early%20breast%20cancer:%20Outcomes%20in%20Chinese%20patients%20in%20the%20APHINITY%20study&amp;author=Z.%20Shao&amp;author=L.-M.%20Tseng&amp;author=C.-S.%20Huang&amp;author=D.%20Pang&amp;author=Y.%20Yang&amp;volume=51&amp;publication_year=2021&amp;pages=345-353&amp;pmid=33619550&amp;doi=10.1093/jjco/hyaa216&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B20-ijms-26-01908">
<span class="label">20.</span><cite>Ahn H.K., Sim S.H., Suh K.J., Kim M.H., Jeong J.H., Kim J.Y., Lee D.W., Ahn J.H., Chae H., Lee K.H., et al.  Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients with ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2022;8:1271–1277. doi: 10.1001/jamaoncol.2022.2310.</cite> [<a href="https://doi.org/10.1001/jamaoncol.2022.2310" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10881214/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35797012/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol.&amp;title=Response%20Rate%20and%20Safety%20of%20a%20Neoadjuvant%20Pertuzumab,%20Atezolizumab,%20Docetaxel,%20and%20Trastuzumab%20Regimen%20for%20Patients%20with%20ERBB2-Positive%20Stage%20II/III%20Breast%20Cancer:%20The%20Neo-PATH%20Phase%202%20Nonrandomized%20Clinical%20Trial&amp;author=H.K.%20Ahn&amp;author=S.H.%20Sim&amp;author=K.J.%20Suh&amp;author=M.H.%20Kim&amp;author=J.H.%20Jeong&amp;volume=8&amp;publication_year=2022&amp;pages=1271-1277&amp;pmid=35797012&amp;doi=10.1001/jamaoncol.2022.2310&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B21-ijms-26-01908">
<span class="label">21.</span><cite>Shao Z., Pang D., Yang H., Li W., Wang S., Cui S., Liao N., Wang Y., Wang C., Chang Y.C., et al.  Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients with Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6:e193692. doi: 10.1001/jamaoncol.2019.3692.</cite> [<a href="https://doi.org/10.1001/jamaoncol.2019.3692" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6813591/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31647503/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Oncol.&amp;title=Efficacy,%20Safety,%20and%20Tolerability%20of%20Pertuzumab,%20Trastuzumab,%20and%20Docetaxel%20for%20Patients%20with%20Early%20or%20Locally%20Advanced%20ERBB2-Positive%20Breast%20Cancer%20in%20Asia:%20The%20PEONY%20Phase%203%20Randomized%20Clinical%20Trial&amp;author=Z.%20Shao&amp;author=D.%20Pang&amp;author=H.%20Yang&amp;author=W.%20Li&amp;author=S.%20Wang&amp;volume=6&amp;publication_year=2020&amp;pages=e193692&amp;pmid=31647503&amp;doi=10.1001/jamaoncol.2019.3692&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B22-ijms-26-01908">
<span class="label">22.</span><cite>Miles D., Ciruelos E., Schneeweiss A., Puglisi F., Peretz-Yablonski T., Campone M., Bondarenko I., Nowecki Z., Errihani H., Paluch-Shimon S., et al.  Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann. Oncol. 2021;32:1245–1255. doi: 10.1016/j.annonc.2021.06.024.</cite> [<a href="https://doi.org/10.1016/j.annonc.2021.06.024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34224826/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann.%20Oncol.&amp;title=Final%20results%20from%20the%20PERUSE%20study%20of%20first-line%20pertuzumab%20plus%20trastuzumab%20plus%20a%20taxane%20for%20HER2-positive%20locally%20recurrent%20or%20metastatic%20breast%20cancer,%20with%20a%20multivariable%20approach%20to%20guide%20prognostication&amp;author=D.%20Miles&amp;author=E.%20Ciruelos&amp;author=A.%20Schneeweiss&amp;author=F.%20Puglisi&amp;author=T.%20Peretz-Yablonski&amp;volume=32&amp;publication_year=2021&amp;pages=1245-1255&amp;pmid=34224826&amp;doi=10.1016/j.annonc.2021.06.024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B23-ijms-26-01908">
<span class="label">23.</span><cite>Von Minckwitz G., Procter M., de Azambuja E., Zardavas D., Benyunes M., Viale G., Suter T., Arahmani A., Rouchet N., Clark E., et al.  Adjuvant Pertuzumab and Trastuzumab in Early HER2- Positive Breast Cancer. N. Engl. J. Med. 2017;377:122–131. doi: 10.1056/NEJMoa1703643.</cite> [<a href="https://doi.org/10.1056/NEJMoa1703643" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5538020/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28581356/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N.%20Engl.%20J.%20Med.&amp;title=Adjuvant%20Pertuzumab%20and%20Trastuzumab%20in%20Early%20HER2-%20Positive%20Breast%20Cancer&amp;author=G.%20Von%20Minckwitz&amp;author=M.%20Procter&amp;author=E.%20de%20Azambuja&amp;author=D.%20Zardavas&amp;author=M.%20Benyunes&amp;volume=377&amp;publication_year=2017&amp;pages=122-131&amp;pmid=28581356&amp;doi=10.1056/NEJMoa1703643&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B24-ijms-26-01908">
<span class="label">24.</span><cite>Kuemmel S., Tondini C.A., Abraham J., Nowecki Z., Itrych B., Hitre E., Karaszewska B., Juárez-Ramiro A., Morales-Vásquez F., Pérez-García J.M., et al.  Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study. Breast Cancer Res. Treat. 2021;187:467–476. doi: 10.1007/s10549-021-06145-3.</cite> [<a href="https://doi.org/10.1007/s10549-021-06145-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8189949/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33748921/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Breast%20Cancer%20Res.%20Treat.&amp;title=Subcutaneous%20trastuzumab%20with%20pertuzumab%20and%20docetaxel%20in%20HER2-positive%20metastatic%20breast%20cancer:%20Final%20analysis%20of%20MetaPHER,%20a%20phase%20IIIb%20single-arm%20safety%20study&amp;author=S.%20Kuemmel&amp;author=C.A.%20Tondini&amp;author=J.%20Abraham&amp;author=Z.%20Nowecki&amp;author=B.%20Itrych&amp;volume=187&amp;publication_year=2021&amp;pages=467-476&amp;pmid=33748921&amp;doi=10.1007/s10549-021-06145-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="B25-ijms-26-01908">
<span class="label">25.</span><cite>Lee Y.P., Lee M.S., Kim H., Kim J.Y., Ahn J.S., Im Y.H., Park Y.H. Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a FirstLine Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer. Cancer Res. Treat. 2022;54:1130–1137. doi: 10.4143/crt.2021.1103.</cite> [<a href="https://doi.org/10.4143/crt.2021.1103" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9582483/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35038825/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Res.%20Treat.&amp;title=Real-World%20Evidence%20of%20Trastuzumab,%20Pertuzumab,%20and%20Docetaxel%20Combination%20as%20a%20FirstLine%20Treatment%20for%20Korean%20Patients%20with%20HER2-Positive%20Metastatic%20Breast%20Cancer&amp;author=Y.P.%20Lee&amp;author=M.S.%20Lee&amp;author=H.%20Kim&amp;author=J.Y.%20Kim&amp;author=J.S.%20Ahn&amp;volume=54&amp;publication_year=2022&amp;pages=1130-1137&amp;pmid=35038825&amp;doi=10.4143/crt.2021.1103&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/11899880/bin/ijms-26-01908-s001.zip" data-ga-action="click_feat_suppl" class="usa-link">ijms-26-01908-s001.zip</a><sup> (108.8KB, zip) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>No new data were created or analyzed in this study.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from International Journal of Molecular Sciences are provided here courtesy of <strong>Multidisciplinary Digital Publishing Institute  (MDPI)</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.3390/ijms26051908"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/ijms-26-01908.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.1 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/11899880/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/11899880/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC11899880%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC11899880/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC11899880/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC11899880/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40076535/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC11899880/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40076535/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC11899880/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/11899880/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="hVX7PVQrJ1wjez1LB1LHKVfdAU6aj7Vsv1ahh7FbxFtSbPq6akXvdCD21A7qKCtJ">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-B7-tgZZA.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-BLbQGH8u.js"></script>
    
    

    </body>
</html>
